Since then, investment and research in this treatment modality have grown exponentially. In 2019, seven of the ten most used medicines on the planet used mAbs.
In 2017, the potential of a new solution for the prevention and treatment of infectious diseases caught the attention of Dr. David Watkins, Dr. Esper Kallas and Dr. Dennis Burton, all three who were previously dedicated to HIV research.
With the complementary scientific talents of Drs., Burton, Watkins and Kallas, along with the many years of business experience of Michael Wyand, MABLOC was born. A dedicated initiative was born to bring a range of mAbs against various infectious diseases and to contribute to the development of effective solutions to current and future pandemics.